CLINICAL TRIALS PROFILE FOR OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

All Clinical Trials for Oxytocin 10 Usp Units In Dextrose 5%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	Northwestern University		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗	Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section	Completed	Basel Women’s University Hospital	Phase 2	1999-01-01	Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.

Clinical Trial Conditions for Oxytocin 10 Usp Units In Dextrose 5%

Condition Name

Condition Name for Oxytocin 10 Usp Units In Dextrose 5%
Intervention	Trials
Postpartum Hemorrhage	81
Healthy	52
Schizophrenia	29

Condition MeSH

Condition MeSH for Oxytocin 10 Usp Units In Dextrose 5%
Intervention	Trials
Hemorrhage	153
Postpartum Hemorrhage	138
Disease	33

Clinical Trial Locations for Oxytocin 10 Usp Units In Dextrose 5%

Trials by Country

Trials by Country for Oxytocin 10 Usp Units In Dextrose 5%
Location	Trials
United States	340
Egypt	81
Canada	63
China	42
France	33

Trials by US State

Trials by US State for Oxytocin 10 Usp Units In Dextrose 5%
Location	Trials
California	59
North Carolina	31
New York	29
Massachusetts	27
South Carolina	19

Clinical Trial Progress for Oxytocin 10 Usp Units In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Oxytocin 10 Usp Units In Dextrose 5%
Clinical Trial Phase	Trials
Phase 4	120
Phase 3	66
Phase 2/Phase 3	16

Clinical Trial Status

Clinical Trial Status for Oxytocin 10 Usp Units In Dextrose 5%
Clinical Trial Phase	Trials
Completed	389
Recruiting	106
Unknown status	97

Clinical Trial Sponsors for Oxytocin 10 Usp Units In Dextrose 5%

Sponsor Name

Sponsor Name for Oxytocin 10 Usp Units In Dextrose 5%
Sponsor	Trials
University of Electronic Science and Technology of China	37
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	29
Cairo University	21

Sponsor Type

Sponsor Type for Oxytocin 10 Usp Units In Dextrose 5%
Sponsor	Trials
Other	964
Industry	47
NIH	38